BWA
INDV icon

Basecamp Wealth Advisors’s Indivior Pharmaceuticals INDV Stock Holding History

Basecamp Wealth Advisors’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16
Closed -$574 – 2103
2025
Q4 		$574 Buy
+16
New +$489 ﹤0.01% 1601

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Basecamp Wealth Advisors's INDV Position: Q1 2026 in Review

Basecamp Wealth Advisors sold out of Indivior Pharmaceuticals (INDV) in Q1 2026, closing a stake of 16 shares — an estimated $574 sold.

Basecamp Wealth Advisors first reported a position in INDV in Q4 2025 and held it in 1 quarter. The position peaked at $574 in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Basecamp Wealth Advisors reported no remaining Indivior Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Basecamp Wealth Advisors sold 16 Indivior Pharmaceuticals shares in Q1 2026, an estimated $574.
  • Basecamp Wealth Advisors first reported a position in Indivior Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Basecamp Wealth Advisors's Indivior Pharmaceuticals position peaked at $574 in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q1 2026, filed 24 Jun 2026.